Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 7.92 2.72% 0.21
BCRX closed up 2.72 percent on Thursday, April 18, 2019, on 1.4 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Earnings due: May 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BCRX trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Inside Day Range Contraction 0.00%
Fell Below 200 DMA Bearish 2.72%
Fell Below 20 DMA Bearish 2.72%
MACD Bearish Signal Line Cross Bearish 2.72%
Expansion Pivot Sell Setup Bearish Swing Setup 2.72%
Wide Range Bar Range Expansion 2.72%
Down 3 Days in a Row Weakness 2.72%
Down 4 Days in a Row Weakness 2.72%

Older signals for BCRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Chemistry Biotechnology Diseases Chemical Compounds Enzymes Gout Seasonal Influenza Acetamides
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.95
52 Week Low 4.76
Average Volume 808,338
200-Day Moving Average 7.7421
50-Day Moving Average 8.4054
20-Day Moving Average 8.263
10-Day Moving Average 8.43
Average True Range 0.4384
ADX 19.16
+DI 16.982
-DI 28.7497
Chandelier Exit (Long, 3 ATRs ) 7.9448
Chandelier Exit (Short, 3 ATRs ) 8.4152
Upper Bollinger Band 9.2025
Lower Bollinger Band 7.3235
Percent B (%b) 0.32
BandWidth 22.739925
MACD Line -0.0273
MACD Signal Line 0.0306
MACD Histogram -0.058
Fundamentals Value
Market Cap 636.99 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -12.77
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.52
Resistance 3 (R3) 8.47 8.21 8.42
Resistance 2 (R2) 8.21 8.06 8.24 8.39
Resistance 1 (R1) 8.07 7.97 8.14 8.12 8.35
Pivot Point 7.81 7.81 7.85 7.84 7.81
Support 1 (S1) 7.67 7.66 7.74 7.72 7.49
Support 2 (S2) 7.41 7.57 7.44 7.45
Support 3 (S3) 7.27 7.41 7.42
Support 4 (S4) 7.32